Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

BACKGROUND: Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes. This randomized, open label phase II study evaluated olaratumab p...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuire, William P., Penson, Richard T., Gore, Martin, Herraez, Antonio Casado, Peterson, Patrick, Shahir, Ashwin, Ilaria, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307114/
https://www.ncbi.nlm.nih.gov/pubmed/30591028
http://dx.doi.org/10.1186/s12885-018-5198-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307114/
https://www.ncbi.nlm.nih.gov/pubmed/30591028
http://dx.doi.org/10.1186/s12885-018-5198-4

Ejemplares similares